Patients with ASXL1 mutations (n = 20) showed a lower hemoglobin level (median, 8.2 vs. 10.6 g/dL, p = 0.043), and patients with ASXL1 chromosome deletion (n = 21; Figure S3) had a higher progression to AML (29% vs. 10%, p = 0.041). Here, ASXL1 is linked to acute myeloid leukemia.